BOSTON--(BUSINESS WIRE)--May 30, 2017--
Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with severe neurological diseases including
amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and
Charcot-Marie-Tooth (CMT), today announced that it will present at the
following upcoming investor conferences in June:
The Jefferies Global Healthcare Conference on June 6, 2017 at 2:30 pm
ET in New York, NY;
The JMP Securities Life Science Conference on June 20, 2017 at 2:00 pm
ET in New York, NY.
A live webcast of Flex Pharma’s presentations at these conferences may
be accessed in the Investor section of the Company’s website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma’s website for 2 weeks following each
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments for cramps and
spasticity associated with the severe neurological diseases including
ALS, MS and Charcot-Marie-Tooth (CMT). Flex Pharma was founded by
National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel
Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of
ion channels and neurobiology, along with Chair and CEO Christoph
Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005689/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications